Nature：司美格鲁肽减重效果发挥至少4年，且保护心血管

Core Viewpoint - The article discusses the long-term effects of the weight loss drug Semaglutide, highlighting its significant benefits for overweight and obese patients over a treatment period of at least four years, including cardiovascular advantages regardless of weight loss [4][10][11]. Group 1: Semaglutide Overview - Semaglutide, marketed as Wegovy, is an injectable prescription medication approved by the FDA in 2021 for chronic weight management, mimicking the structure of the human hormone GLP-1 to regulate appetite and blood sugar levels [6]. - The drug induces feelings of fullness and slows gastric emptying, reducing the likelihood of overeating, and also helps in blood sugar regulation, being a key component of Ozempic, which is aimed at treating type 2 diabetes [6]. Group 2: Long-term Effects of Semaglutide - A study published in Nature Medicine analyzed the effects of Semaglutide over four years, involving over 17,600 adults who were overweight or obese with a history of cardiovascular disease but without diabetes [8]. - On average, participants using Semaglutide experienced a weight loss of 10% and a reduction in waist circumference of approximately 3 inches, compared to a 1.5% weight loss and 0.5-inch waist reduction in the placebo group [8]. Group 3: Cardiovascular Benefits - A separate study using the same dataset found that Semaglutide treatment provided cardiovascular benefits regardless of participants' initial weight and the amount of weight lost [11]. - The findings suggest that Semaglutide's therapeutic effects extend beyond weight loss, potentially lowering cardiovascular risks through positive impacts on blood sugar, blood pressure, inflammation, and direct effects on the heart and blood vessels [11].